News

Existing medications may fight coronavirus infection

Existing medications may fight coronavirus infection
Science
University of New Mexico researchers who combed through a "library" of previously approved drugs believe they have identified a medication with the potential to help speed a patient s recovery from SARS-CoV-2 infection.

advertisement

"The gist of it is we think we found a drug that is on par with remdesivir and is much cheaper," said Tudor Oprea, MD, PhD, professor of Medicine and Pharmaceutical Sciences and chief of the UNM Division of Translational Informatics. Remdesivir is a relatively new antiviral medication that has been shown to shorten hospital stays for those recovering from the novel coronavirus.

In a paper published this week in ACS Pharmacology & Translational Science, Oprea and his colleagues, in partnership with a team at the University of Tennessee Health Science Center led by professor Colleen Jonsson, PhD, reported that an older antimalarial drug called amodiaquine was effective in eradicating the virus in test tube experiments.

Tudor Oprea, MD, PhDIt was one of three promising candidates identified in a process that entailed studying the molecular characteristics of about 4,000 drugs approved for human use by the Food and Drug Administration and other agencies. The researchers hoped to find drugs that would target known vulnerabilities in the virus.

Combining two drugs could mean that lower doses of each could be administered, lessening the likelihood of adverse reactions, he said.s Administering two drugs also makes it less likely that the virus would develop a mutation rendering it immune from the treatment.

"Think of it as a whack-a-mole game," Oprea said. "Instead of having one hammer, you have two hammers, which is more effective. We re trying to give the scientific community two hammers instead of one."

Many compounds that show antiviral activity in a laboratory setting don t have the same effect in living organisms, Oprea notes, so the next step is to mount clinical trials to see whether the medications work in COVID-positive patients.

The UNM drug screening process started with Oprea and his colleague Larry Sklar, PhD, Distinguished Professor in the Department of Pathology. They used computational methods to identify candidate drugs by gauging their similarity to hydroxychloroquine, a since-discredited antimalarial medication that had been widely touted as a COVID-19 treatment. Because of molecular variations in some of the drugs, more than 6,000 combinations were assessed.

Likely candidates were forwarded to Steven Bradfute, PhD, assistant professor in the Center for Global Health, who tested the compounds against samples of the virus in his Biosafety Level-3 laboratory. Later, the experiments were repeated by the University of Tennessee scientists to provide independent confirmation of the findings -- and they used an additional test that reveals the drugs potency against the virus, Oprea said.

Amodiaquine, first made in 1948, is on the World Health Organization s List of Essential Medicines. It has a good safety profile and is widely used in Africa to treat malaria. Zuclophentixol has been used to treat schizophrenia since the 1970s, while nebivolol has been used for hypertension since the late 1990s.

In addition to Oprea, Sklar and Bradfute, UNM faculty members participating in the study included Giovanni Bocci and Cristian Bologa from the Translational Informatics Division, Chunyan Ye and Douglas J. Perkins from the Center for Global Health and Matthew J. Garcia from the Center for Molecular Discovery.

Materials provided by . Original written by Michael Haederle. Note: Content may be edited for style and length.

University of New Mexico Health Sciences Center. "Existing medications may fight coronavirus infection." ScienceDaily. ScienceDaily, 16 October 2020. .

University of New Mexico Health Sciences Center. "Existing medications may fight coronavirus infection." ScienceDaily. www.sciencedaily.com/releases/2020/10/201016143047.htm (accessed October 16, 2020).

advertisement

1

Oct. 15, 2020 — A new study identifies drug targets common to all three coronaviruses (SARS-CoV-2, SARS-CoV-1, and MERS-CoV) and potential drugs that could be repurposed as COVID-19 treatments. Researchers suggest ...

Sep. 23, 2020 — Researchers have built an interactome that includes the lung-epithelial cell host interactome integrated with a SARS-CoV-2 interactome. Applying network biology analysis tools to this ...

July 24, 2020 — A new study has identified 21 existing drugs that stop the replication of SARS-CoV-2, the virus that causes ...

June 10, 2020 — Researchers have identified a set of potential immunodominant epitopes from the SARS-CoV-2 proteome. These epitopes are capable of generating both antibody- and cell-mediated immune responses. The ...
Read more on sciencedaily.com
News Topics :
RELATED STORIES :
Science
American and Polish scientists, reporting Oct. 16 in the journal Science Advances, laid out a novel rationale for COVID 19 drug design blocking a molecular scissor that the virus uses...
Science
To identify new potential therapeutic targets for SARS CoV 2, a team of scientists at the New York Genome Center, New York University, and the Icahn School of Medicine at Mount Sinai,...
Science
There are no Food and Drug Administration FDA approved treatments for COVID 19, the pandemic infection caused by a novel coronavirus. While several therapies are being tested in clinical trials, current standard...
Science
People have different susceptibilities to SARS CoV 2, the virus behind the COVID 19 pandemic, and develop varying degrees of fever, fatigue, and breathing problems common symptoms of the illness. What might...
Science
The news about remdesivir, the investigational anti viral drug that has shown early promise in the fight against COVID 19, keeps getting better. advertisement This week researchers at Vanderbilt University Medical Center...